IGF1R and neoplasm: Further experiments confirmed that the combined inhibition of IGF-1R (e.g., with linsitinib) or PI3K (e.g., with buparlisib) significantly enhanced the antitumor effects of BLZ945 and prolonged survival in tumor-bearing mice [62].